Key Updates: Vision Loss Focus: While gastrointestinal claims are ongoing, cases involving NAION (blindness) are emerging as some of the strongest claims due to the sudden and permanent nature of the injury
Be sure to disclose these during screening
Dose-dependent Action of Zingiber officinale on Colonic Dysmotility and Ex Vivo Spontaneous Intestinal Contraction Modulation
Weight loss plateau Some patients initially lose weight on semaglutide but eventually reach a plateau
Still, these effects are largely theoretical for humans based mostly on short-term lab data, not clinical human trials
Exenatide GLP-RA , 1995 2005 .60 Liraglutide 2010 2 ,62 lixisenatide 2013 2 , 2 016 7 .63 (Albiglutide) 2014 3 , 2014 4 .64 (Dulaglutide) 2014 9 T2DM ,65 (Semaglutide) 2017 9 .66 (Beinaglutide) GLP-RA , 2016 9 T2DM .67 PEG-(PEG-loxenatide) GLP-RA , 2019 5 .66 ( 1 2) Table 1 Comparison of GLP-1RAs used in type 2 diabetes mellitus DateBrand nameGLP-1RAHalf-lifeDose (SC)Molecular formulaClinial trial focus Table 2 Comparative overview of efficacy and adverse effects of mainstream GLP-1RA medications Current GLP-1RAs GLP-1RAs are synthetic protein preparations that have partial or complete amino acid sequence homology with GLP-1 found in the body, are not easily degraded, have longer half-lives and have stronger biological activity
.jpg)
